Imunon, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
Imunon, Inc. (IMNN) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price of $40.23 per share for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-11.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice · last filed 2018-05-11
- Imunon, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2018-03-31 was $40.23, a 205.93% increase year-over-year.
- Imunon, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2017-03-31 was $13.15, a 7.43% increase year-over-year.
- Imunon, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2016-03-31 was $12.24, a 50.30% decline year-over-year.
- Imunon, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2015-03-31 was $24.63, a 27.86% decline year-over-year.
- Imunon, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2017 was $164.12, a 20.72% increase from fiscal 2016.
- Imunon, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2016 was $135.95, a 2345.14% increase from fiscal 2015.
- Imunon, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2015 was $5.56, a 70.81% decline from fiscal 2014.
- Imunon, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2014 was $19.05, a 13.46% increase from fiscal 2013.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 12 month as first filed |
|---|---|---|---|---|---|
| 2018-03-31 | $40.23 10-Q · filed 2018-05-11 | ||||
| 2017-12-31 | $164.12 10-K · filed 2018-03-27 | ||||
| 2017-09-30 | $164.12 10-Q · filed 2017-11-14 | ||||
| 2017-06-30 | $157.97 10-Q · filed 2017-08-14 | ||||
| 2017-03-31 | $13.15 10-Q · filed 2017-05-12 | ||||
| 2016-12-31 | $135.95 10-K · filed 2018-03-27 | $9.71 10-K · filed 2017-03-24 | |||
| 2016-09-30 | $10.68 10-Q · filed 2016-11-10 | ||||
| 2016-06-30 | $12.36 10-Q · filed 2016-08-15 | ||||
| 2016-03-31 | $12.24 10-Q · filed 2016-05-16 | ||||
| 2015-12-31 | $5.56 10-K · filed 2017-03-24 | ||||
| 2015-09-30 | $9.65 10-Q · filed 2015-11-05 | ||||
| 2015-06-30 | $10.83 10-Q · filed 2015-08-10 | ||||
| 2015-03-31 | $24.63 10-Q · filed 2015-05-11 | ||||
| 2014-12-31 | $19.05 10-K · filed 2016-03-30 | ||||
| 2014-09-30 | $20.15 10-Q · filed 2014-11-10 | ||||
| 2014-06-30 | $22.31 10-Q · filed 2014-08-07 | ||||
| 2014-03-31 | $34.14 10-Q · filed 2014-05-08 | ||||
| 2013-12-31 | $16.79 10-K · filed 2016-03-30 | ||||
| 2013-09-30 | $17.10 10-Q · filed 2013-11-12 | ||||
| 2013-06-30 | $6.45 10-Q · filed 2013-08-08 | ||||
| 2013-03-31 | $6.45 10-Q · filed 2013-05-09 | ||||
| 2012-12-31 | $29.43 10-K · filed 2015-03-12 | $6.54 10-K · filed 2013-03-18 | |||
| 2012-09-30 | $6.80 10-Q · filed 2012-11-09 | ||||
| 2012-06-30 | $7.57 10-Q · filed 2012-08-14 | ||||
| 2011-12-31 | $14.54 10-K · filed 2014-03-13 | $3.23 10-K · filed 2013-03-18 | |||
| 2010-12-31 | $3.03 10-K · filed 2013-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |